There’s an urgent need for new treatment options for ovarian cancer patients who are often diagnosed at advanced stages when survival outcomes are worse. Cartherics’ lead cell therapy CTH-401 is a natural killer (NK) cell product designed to seek out and destroy the cells that cause ovarian cancer, with clinical trials planned for early next year. Read more in the Herald Sun:

Digital article, 11 February 2024 – Ovarian cancer: Biotech company Cartherics to start human trials of new drug

Herald Sun, 12 February 2024, Page 13 – Cancer killer trial close

and

Herald Sun editorial, 12 February, 2024, Page 22 – Local hope in cancer trial